Howard Lovy - Arrowhead Pharmaceuticals Director Communications
| HDP1 Stock | EUR 15.94 0.06 0.38% |
Insider
Howard Lovy is Director Communications of Arrowhead Pharmaceuticals
| Phone | 626 304 3400 |
| Web | https://arrowheadpharma.com |
Arrowhead Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1285) % which means that it has lost $0.1285 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4043) %, meaning that it generated substantial loss on money invested by shareholders. Arrowhead Pharmaceuticals' management efficiency ratios could be used to measure how well Arrowhead Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| BBUS CA | Insurance Australia Group | N/A | |
| Gang Liu | Sinopec Shanghai Petrochemical | 51 | |
| Peilin Wang | Sinopec Shanghai Petrochemical | N/A | |
| Jarrod Hill | Insurance Australia Group | N/A | |
| MAICD FCPA | QBE Insurance Group | N/A | |
| Peter Horton | Insurance Australia Group | N/A | |
| Zemin Guan | Sinopec Shanghai Petrochemical | 59 | |
| Julie Batch | Insurance Australia Group | N/A | |
| Jason BSc | QBE Insurance Group | 56 | |
| BAgr AMP | Insurance Australia Group | 57 | |
| BCom BCom | Insurance Australia Group | 54 | |
| Xiangyu Huang | Sinopec Shanghai Petrochemical | 55 | |
| Peter BCom | Insurance Australia Group | N/A | |
| Sze ACS | Sinopec Shanghai Petrochemical | 41 | |
| Amanda Whiting | Insurance Australia Group | N/A | |
| BA ACA | QBE Insurance Group | N/A | |
| Feng Zhang | Sinopec Shanghai Petrochemical | 54 | |
| Jun Du | Sinopec Shanghai Petrochemical | 53 | |
| Tao Wan | Sinopec Shanghai Petrochemical | N/A | |
| Ashley Dalziell | QBE Insurance Group | N/A | |
| Christine BA | Insurance Australia Group | N/A | |
Management Performance
| Return On Equity | -0.4 | |||
| Return On Asset | -0.13 |
Arrowhead Pharmaceuticals Leadership Team
Elected by the shareholders, the Arrowhead Pharmaceuticals' board of directors comprises two types of representatives: Arrowhead Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arrowhead. The board's role is to monitor Arrowhead Pharmaceuticals' management team and ensure that shareholders' interests are well served. Arrowhead Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arrowhead Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tracie Oliver, Chief Officer | ||
| Kenneth Myszkowski, Chief Officer | ||
| Christopher Anzalone, President CEO, Director | ||
| Javier MD, Chief Officer | ||
| PharmD JD, COO Counsel | ||
| Howard Lovy, Director Communications | ||
| Vincent CFA, Head VP | ||
| Mark Davis, Founder Calando | ||
| MBA MD, VP Medicine | ||
| Mark Seefeld, Head VP |
Arrowhead Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arrowhead Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.56) % | |||
| Operating Margin | (0.57) % | |||
| Current Valuation | 2.76 B | |||
| Shares Outstanding | 108.31 M | |||
| Shares Owned By Insiders | 4.93 % | |||
| Shares Owned By Institutions | 69.27 % | |||
| Price To Earning | 263.63 X | |||
| Price To Book | 8.32 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Arrowhead Stock
When determining whether Arrowhead Pharmaceuticals is a strong investment it is important to analyze Arrowhead Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Arrowhead Pharmaceuticals' future performance. For an informed investment choice regarding Arrowhead Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Arrowhead Stock please use our How to Invest in Arrowhead Pharmaceuticals guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.